Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Saposin C protects glucocerebrosidase against α-synuclein inhibition.

Biochemistry - 15 Oct 2013

Yap Thai Leong, Gruschus James M, Velayati Arash, Sidransky Ellen, Lee Jennifer C

Abstract excerpt

Mutations in GBA1, the gene for glucocerebrosidase (GCase), are genetic risk factors for Parkinson disease (PD). α-Synuclein (α-Syn), a protein implicated in PD, interacts with GCase and efficiently inhibits enzyme activity. GCase deficiency causes the lysosomal storage disorder Gaucher disease (...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Enzyme Inhibitors
Share to Glucosylceramidase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kinetics

Share to Models, Molecular

Share to Parkinson Disease

Share to Protein Binding

Share to Saposins

Source

Open in PubMed Open full text

Identifiers

PMID: 24070323
DOI: 10.1021/bi401191v
PMCID: PMC3833811

Genes

GBA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24070323-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Saposin C protects glucocerebrosidase against α-synuclein inhibition.PMID 24070323Read ↗

Glucocerebrosidase rescues alpha-synuclein from amyloid formationSemantic proximity Read ↗

Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.Semantic proximity Read ↗

The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson’s diseaseSemantic proximity Read ↗

Glucocerebrosidase as a therapeutic target for Parkinson's disease.Semantic proximity Read ↗

Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.Semantic proximity Read ↗

A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.Semantic proximity Read ↗

Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.Semantic proximity Read ↗

Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models.Semantic proximity Read ↗

Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.Semantic proximity Read ↗

Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy.Semantic proximity Read ↗

Targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct.Semantic proximity Read ↗

Gaucher-Associated Parkinsonism.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.